WEDNESDAY, July 28, 2021 (HealthDay News) — An outside advisor to the U.S. Food and Drug Administration’s review of the controversial Alzheimer’s drug Aduhelm is now speaking out, arguing that the approval was based on dodgy science and involved questionable collaboration between regulators and the drug’s maker. “I’m not surprisedContinue Reading